MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
MapLight Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.00+0.30 (+3.90%)
Close on Oct 19, 2026
- Market cap
- $363.45M
- P/E (TTM)
- –
- Dividend yield
- –
MapLight Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Market Cap | $371.02M | $166.30M |
| Enterprise Value | $66.30M | $88.19M |
| PB Ratio | 1.07 | 2.03 |
| P/TBV Ratio | 1.07 | 2.29 |
Income (trailing twelve months)
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$242.93M | -$21.40M |
| Net Income | -$229.83M | -$22.46M |
| EBITDA | -$242.93M | -$16.91M |
Returns
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -445.2% | -53.2% |
| Return on Assets (ROA) | -62.4% | -40.9% |
| Return on Capital Employed (ROCE) | -69.6% | -38.1% |
Balance sheet
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $304.73M | $61.43M |
| Net Cash (Debt) | $304.73M | $15.35M |
| Net Cash Per Share | $6.57 | $0.66 |
| Equity (Book Value) | $348.30M | $49.09M |
| Book Value Per Share | $7.51 | $1.37 |
| Tangible Book Value | $348.30M | $23.52M |
| Working Capital | $299.49M | $76.81M |
Financial position
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 16.52 | 3.34 |
| Quick Ratio | 15.79 | 2.44 |
Cash flow (trailing twelve months)
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$174.67M | -$12.35M |
| Capital Expenditures | -$453.00K | -$1.08M |
| Free Cash Flow | -$175.12M | -$20.22M |
| FCF Per Share | -$3.78 | -$0.42 |
Efficiency
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.73M | -$703.34K |
| Employee Count | 133 | 74 |
Dividends and yields
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -61.9% | -23.3% |
| FCF Yield | -47.2% | -8.72% |
Shares
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 46,377,800 | 58,127,000 |
| Shares Change (QoQ) | 0.50% | 0.54% |
| Shares Held by Institutions | 56.6% | 59.4% |
Scores
| Measure | MapLight Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 8.07 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from MapLight Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.